- Home
- PHAT vs COLL Comparison
PHAT vs COLL Comparison
Compare PHAT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- COLL
- Stock Information
- Founded
- PHAT 2018
- COLL 2002
- Country
- PHAT United States
- COLL United States
- Employees
- PHAT N/A
- COLL N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- PHAT Health Care
- COLL Health Care
- Exchange
- PHAT Nasdaq
- COLL Nasdaq
- Market Cap
- PHAT 1.2B
- COLL 1.1B
- IPO Year
- PHAT 2019
- COLL 2015
- Fundamental
- Price
- PHAT $8.78
- COLL $29.58
- Analyst Decision
- PHAT Strong Buy
- COLL Strong Buy
- Analyst Count
- PHAT 4
- COLL 6
- Target Price
- PHAT $22.50
- COLL $42.00
- AVG Volume (30 Days)
- PHAT 1.9M
- COLL 440.1K
- Earning Date
- PHAT 11-07-2024
- COLL 11-07-2024
- Dividend Yield
- PHAT N/A
- COLL N/A
- EPS Growth
- PHAT N/A
- COLL 757.11
- EPS
- PHAT N/A
- COLL 2.16
- Revenue
- PHAT $26,270,000.00
- COLL $599,245,000.00
- Revenue This Year
- PHAT $6,714.96
- COLL $13.02
- Revenue Next Year
- PHAT $293.69
- COLL $18.01
- P/E Ratio
- PHAT N/A
- COLL $13.68
- Revenue Growth
- PHAT N/A
- COLL 9.62
- 52 Week Low
- PHAT $6.07
- COLL $25.07
- 52 Week High
- PHAT $19.71
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- PHAT 23.73
- COLL 26.96
- Support Level
- PHAT $8.91
- COLL $29.69
- Resistance Level
- PHAT $19.05
- COLL $35.62
- Average True Range (ATR)
- PHAT 1.74
- COLL 1.41
- MACD
- PHAT -1.05
- COLL -0.39
- Stochastic Oscillator
- PHAT 2.19
- COLL 6.36
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.